Literature DB >> 20299968

Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation.

John C Probasco1, Steven G Deeks, Evelyn Lee, Rebecca Hoh, Peter W Hunt, Teri Liegler, Richard W Price, Serena S Spudich.   

Abstract

BACKGROUND: A subset of HIV-infected patients, termed 'elite' viral controllers, maintain undetectable plasma HIV RNA levels in the absence of therapy. In this group, host-mediated viral control may be accompanied by chronic systemic inflammation. It is unknown whether either infection or chronic inflammation is present within the central nervous system of these individuals.
METHODS: Cross-sectional analysis compared cerebrospinal fluid (CSF) HIV RNA and biomarkers of intrathecal inflammation in eight controllers (plasma HIV RNA levels <50 copies/ml) with 26 HIV-uninfected individuals, 25 untreated individuals HIV-infected, viremic individuals, and 23 HIV-infected individuals with treatment-mediated viral suppression (plasma HIV RNA levels <50 copies/ml).
RESULTS: All controllers had CSF HIV RNA levels below 2.5 copies/ml. CSF white blood cell (WBC) counts and CSF: plasma albumin ratios in the controllers were similar to those in both HIV-uninfected individuals and antiretroviral therapy-suppressed HIV-infected individuals. CSF neopterin, MCP-1, and IP-10 concentrations were also not different in the controllers from either HIV-uninfected or treated HIV-infected individuals.
CONCLUSION: The character of CSF HIV infection and degree of immunoactivation in controllers is comparable to that of HIV-uninfected and antiretroviral therapy-suppressed HIV-infected individuals, but distinct from that of untreated, viremic HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20299968     DOI: 10.1097/QAD.0b013e328331e15b

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

Review 1.  Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.

Authors:  Suzi Hong; William A Banks
Journal:  Brain Behav Immun       Date:  2014-10-22       Impact factor: 7.217

2.  Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers.

Authors:  Viktor Dahl; Julia Peterson; Serena Spudich; Evelyn Lee; Barbara L Shacklett; Richard W Price; Sarah Palmer
Journal:  AIDS       Date:  2013-04-24       Impact factor: 4.177

3.  Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-naïve HIV-infected Thais.

Authors:  Lishomwa C Ndhlovu; Michelle L D'Antoni; Jintanat Ananworanich; Mary Margaret Byron; Thep Chalermchai; Pasiri Sithinamsuwan; Somporn Tipsuk; Erika Ho; Bonnie M Slike; Alexandra Schuetz; Guangxiang Zhang; Melissa Agsalda-Garcia; Bruce Shiramizu; Cecilia M Shikuma; Victor Valcour
Journal:  J Neuroimmunol       Date:  2015-09-04       Impact factor: 3.478

4.  Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression.

Authors:  Magnus Gisslen; Sheila M Keating; Serena Spudich; Victor Arechiga; Sophie Stephenson; Henrik Zetterberg; Clara Di Germanio; Kaj Blennow; Dietmar Fuchs; Lars Hagberg; Philip J Norris; Julia Peterson; Barbara L Shacklett; Constantin T Yiannoutsos; Richard W Price
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

5.  The cerebrospinal fluid proteome in HIV infection: change associated with disease severity.

Authors:  Thomas E Angel; Jon M Jacobs; Serena S Spudich; Marina A Gritsenko; Dietmar Fuchs; Teri Liegler; Henrik Zetterberg; David G Camp; Richard W Price; Richard D Smith
Journal:  Clin Proteomics       Date:  2012-03-20       Impact factor: 3.988

6.  Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.

Authors:  Julia Peterson; Magnus Gisslen; Henrik Zetterberg; Dietmar Fuchs; Barbara L Shacklett; Lars Hagberg; Constantin T Yiannoutsos; Serena S Spudich; Richard W Price
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

7.  Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.

Authors:  Anupama Ganesh; Donna Lemongello; Evelyn Lee; Julia Peterson; Bridget E McLaughlin; April L Ferre; Geraldine M Gillespie; Dietmar Fuchs; Steven G Deeks; Peter W Hunt; Richard W Price; Serena S Spudich; Barbara L Shacklett
Journal:  AIDS Res Hum Retroviruses       Date:  2016-05-02       Impact factor: 2.205

8.  Cell-Mediated Immunity in Elite Controllers Naturally Controlling HIV Viral Load.

Authors:  Luca Genovese; Manuela Nebuloni; Massimo Alfano
Journal:  Front Immunol       Date:  2013-04-09       Impact factor: 7.561

9.  CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF.

Authors:  Sam Nightingale; Benedict D Michael; Martin Fisher; Alan Winston; Mark Nelson; Steven Taylor; Andrew Ustianowski; Jonathan Ainsworth; Richard Gilson; Lewis Haddow; Edmund Ong; Clifford Leen; Jane Minton; Frank Post; Apostolos Beloukas; Ray Borrow; Munir Pirmohamed; Anna Maria Geretti; Saye Khoo; Tom Solomon
Journal:  Cytokine       Date:  2016-04-28       Impact factor: 3.861

10.  HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Authors:  Timothy J Henrich; Hiroyu Hatano; Oliver Bacon; Louise E Hogan; Rachel Rutishauser; Alison Hill; Mary F Kearney; Elizabeth M Anderson; Susan P Buchbinder; Stephanie E Cohen; Mohamed Abdel-Mohsen; Christopher W Pohlmeyer; Remi Fromentin; Rebecca Hoh; Albert Y Liu; Joseph M McCune; Jonathan Spindler; Kelly Metcalf-Pate; Kristen S Hobbs; Cassandra Thanh; Erica A Gibson; Daniel R Kuritzkes; Robert F Siliciano; Richard W Price; Douglas D Richman; Nicolas Chomont; Janet D Siliciano; John W Mellors; Steven A Yukl; Joel N Blankson; Teri Liegler; Steven G Deeks
Journal:  PLoS Med       Date:  2017-11-07       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.